Phase I study of antilipopolysaccharide human monoclonal antibody MAB-T88.
Monoclonal antibody MAB-T88 is a human monoclonal immunoglobulin M antibody directed at the lipopolysaccharide of gram-negative bacteria. In this study, nine patients who were expected to become neutropenic from antineoplastic chemotherapy received an infusion of MAB-T88, three patients at each of three doses: 1, 4, and 8 mg/kg of body weight. MAB-T88 was shown to be safe, with an effective half-life in plasma of 25.4 h, and no patient developed immunoglobulin G antibody to MAB-T88.
Daifuku
R
R
Chiron Corporation, Emeryville, California 94608-2997.
Haenftling
K
K
Young
J
J
Groves
E S
ES
Turrell
C
C
Meyers
F J
FJ
D000911:Antibodies, Monoclonal / Q000008:administration & dosage* / Q000097:blood; D004797:Enzyme-Linked Immunosorbent Assay; D006207:Half-Life; D006801:Humans; D007136:Immunoglobulins / Q000276:immunology*; D007262:Infusions, Intravenous
D000911:Antibodies, Monoclonal; D007136:Immunoglobulins; C042866:antilipopolysaccharide antibodies